title: CD36 as a target to prevent cardiac lipotoxicity and insulin resistance.
abstract: The fatty acid transporter and scavenger receptor CD36 is increasingly being implicated in the pathogenesis of insulin resistance and its progression towards type 2 diabetes and associated cardiovascular complications. The redistribution of CD36 from intracellular stores to the plasma membrane is one of the earliest changes occurring in the heart during diet induced obesity and insulin resistance. This elicits an increased rate of fatty acid uptake and enhanced incorporation into triacylglycerol stores and lipid intermediates to subsequently interfere with insulin-induced GLUT4 recruitment (i.e., insulin resistance). In the present paper we discuss the potential of CD36 to serve as a target to rectify abnormal myocardial fatty acid uptake rates in cardiac lipotoxic diseases. Two approaches are described: (i) immunochemical inhibition of CD36 present at the sarcolemma and (ii) interference with the subcellular recycling of CD36. Using in vitro model systems of high-fat diet induced insulin resistance, the results indicate the feasibility of using CD36 as a target for adaptation of cardiac metabolic substrate utilization. In conclusion, CD36 deserves further attention as a promising therapeutic target to redirect fatty acid fluxes in the body.
authors.affiliation: Department of Molecular Genetics, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands. glatz@maastrichtuniversity.nl
authors.forename: Jan F C
authors.initials: JF
authors.lastname: Glatz
authors.forename: Yeliz
authors.initials: Y
authors.lastname: Angin
authors.forename: Laura K M
authors.initials: LK
authors.lastname: Steinbusch
authors.forename: Robert W
authors.initials: RW
authors.lastname: Schwenk
authors.forename: Joost J F P
authors.initials: JJ
authors.lastname: Luiken
mesh_terms: D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D018955:CD36 Antigens / Q000737:chemistry / Q000378:metabolism*; D058065:Diabetic Cardiomyopathies / Q000378:metabolism / Q000517:prevention & control*; D006321:Heart / Q000187:drug effects; D006801:Humans; D007333:Insulin Resistance; D050356:Lipid Metabolism / Q000187:drug effects; D008082:Lipotropic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D049990:Membrane Transport Modulators / Q000494:pharmacology / Q000627:therapeutic use*; D058990:Molecular Targeted Therapy; D009206:Myocardium / Q000378:metabolism*
chemical_list: D018955:CD36 Antigens; D008082:Lipotropic Agents; D049990:Membrane Transport Modulators